Evaluation of curcumin effect on prevention of hepatotoxicity

Phase 3

• Conditions: cancer.; Malignant neoplasm of central portion of breast; C50.1

• Registration Number: IRCT20190918044815N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Age 30 to 60 years
Definitive diagnosis of cancer that chemotherapyeutic treatment is indicated .
Treated with a regimen containing paclitaxel and docetaxel
Ability to take oral medication

Exclusion Criteria

Gastrointestinal bleeding
pregnancy and Breastfeeding
using heparin, aspirin, Clopidogrel, dipiridamol ,warfarin and ticlopidine
Past medical history of hepatic disease
Past medical history of peptic ulcer

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Aspartate Aminotransferase. Timepoint: before intervention and 3 and 6 weeks after intervention. Method of measurement: laboratory.;Alanine transaminase. Timepoint: before intervention and 3 and 6 weeks after intervention. Method of measurement: laboratory.;Alkaline phosphatase. Timepoint: before intervention and 3 and 6 weeks after intervention. Method of measurement: laboratory.;Bilirubin. Timepoint: before intervention and 3 and 6 weeks after intervention. Method of measurement: laboratory.